Anticoagulants 发表于 2025-3-26 20:57:04

http://reply.papertrans.cn/23/2220/221972/221972_31.png

职业拳击手 发表于 2025-3-27 04:10:33

http://reply.papertrans.cn/23/2220/221972/221972_32.png

细查 发表于 2025-3-27 08:26:37

http://reply.papertrans.cn/23/2220/221972/221972_33.png

Engulf 发表于 2025-3-27 12:25:03

The Genetic Basis of Essential Hypertension and Its Implications for Treatment,bution in the general population with no natural hypertensive threshold. Decisions regarding who to treat and with what drugs are based upon morbidity and mortality data in large population studies, the presence/absence of co-existing disease and cost. Because of variation between individuals in the

monochromatic 发表于 2025-3-27 15:56:10

Genetic Predisposition to Cardiac Hypertrophy,de and nature of the response is influenced by both genetic and nongenetic factors. Mutations in single genes underlie hypertrophic cardiomyopathy (HCM) but there is remarkable variability in the phenotypic expression of HCM. Both the genetic background, referred to as the modifier genes, and probab

FIS 发表于 2025-3-27 19:12:14

http://reply.papertrans.cn/23/2220/221972/221972_36.png

cutlery 发表于 2025-3-28 01:04:32

http://reply.papertrans.cn/23/2220/221972/221972_37.png

锯齿状 发表于 2025-3-28 03:17:13

http://reply.papertrans.cn/23/2220/221972/221972_38.png

maculated 发表于 2025-3-28 09:02:18

http://reply.papertrans.cn/23/2220/221972/221972_39.png

全面 发表于 2025-3-28 11:29:07

Association of Thrombotic Disease with Genetic Polymorphism of Haemostatic Genes: Relevance to Pharr protein expression levels or encoding protein structure alteration affecting function have mechanistically clear effects on thrombin generation or fibrinolysis, which correlate with increased risk of VT. About half the incidence of VT can be attributed to these genetic variants. The risk of VT con
页: 1 2 3 [4] 5 6
查看完整版本: Titlebook: Cardiovascular Pharmacogenetics; Martin R. Wilkins (Professor) Book 2004 Springer-Verlag Berlin Heidelberg 2004 Cardiovascular Disease.Gen